TAK-960 dihydrochloride is an orally administered, selective polo-like kinase 1 (PLK1) inhibitor, exhibiting a potent IC 50 of 0.8 nM. It also targets PLK2 and PLK3 with IC 50 values of 16.9 and 50.2 nM, respectively. This compound effectively inhibits the proliferation of a broad range of cancer cell lines and demonstrates substantial efficacy against various tumor xenografts.